Interestingly, a recent paper describes the reductionof CHI3L1 levels in CSF of MS patients treated with fingolimod, postulatingthat this protein is an efficacy biomarker related with the inflammationdecrease produced by the drug treatment. These findings are aligned with the outcomes from the LBVS conductedin this study. This evidence concerns the gene CHI3L1 and myeloid sarcoma.